Clinical Trials · NCT07282613
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 80
- Start date
- Aug 2026
- Locations
- 56 sites, 10 countries
- Primary endpoint
- Change in glycated haemoglobin (HbA1c)